Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
IPO Year:
Exchange: NASDAQ
Website: savarapharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2025 | $7.00 | Overweight | Wells Fargo |
| 8/15/2025 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 5/29/2025 | $2.00 | Buy → Neutral | H.C. Wainwright |
| 12/20/2024 | $8.00 | Overweight | Wells Fargo |
| 11/13/2024 | $7.00 → $5.00 | Outperform → In-line | Evercore ISI |
| 2/15/2024 | $8.00 | Mkt Outperform | JMP Securities |
| 11/7/2023 | $7.00 | Buy | Guggenheim |
| 5/16/2023 | $2.00 → $4.00 | Hold → Buy | Jefferies |
| 3/31/2023 | $2.00 | Buy → Hold | Jefferies |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
8-K - Savara Inc (0001160308) (Filer)
144 - Savara Inc (0001160308) (Subject)
SCHEDULE 13D/A - Savara Inc (0001160308) (Subject)
10-Q - Savara Inc (0001160308) (Filer)
424B5 - Savara Inc (0001160308) (Filer)
8-K - Savara Inc (0001160308) (Filer)
424B5 - Savara Inc (0001160308) (Filer)
8-K - Savara Inc (0001160308) (Filer)
8-K - Savara Inc (0001160308) (Filer)
10-Q - Savara Inc (0001160308) (Filer)
Fastest customizable press release news feed in the world
--Savara Submitted the MOLBREEVI Biologics License Application (BLA) in December 2025 for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)-- PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced an exclusive distribution agreement for MOLBREEVI. Savara submitted the MOLBREEVI BLA to the U.S. Food and Drug Administration (FDA) in December 2025 for the treatment of autoimmune PAP. Priority Review was requested. If approved, PANTHERx and its team of rare c
-- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Priority Review was Requested -- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the MOLBREEVI BLA to the FDA, with Fujifilm as the drug substance manufacturer. The MOLBREEVI BLA submission is seeking approval for the treatment of autoimmune PAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. The Company has requested Priority Review of the application. MOLBREEVI was granted Fast Track and Breakthrough
Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will present and host one on one meetings at the 44th Annual J.P. Morgan Healthcare Conference. Date/Time of Presentation: Wednesday, January 14, 5:15pm PT/8:15pm ET Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara Location: Westin St. Francis, San Francisco, Elizabethan B Room The live webcast and subsequent replay will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 30 days. About Savara Savara is a clinical stage biopharmaceutical
-- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI Delivered Via PARI's Proprietary eFlow® Nebulizer System -- Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its intention to grant a patent application covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). "The liquid formulation and drug-device patents will provide prot
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496 611 titled, "Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution." The patent is jointly held by Savara and PARI and covers the combination of Savara's investigational therapy, MOLBREEVI, and PARI's investigational eFlow® Nebulizer System that has been optimized for the delivery of MOLBREEVI. "This patent covers our drug-device combination through March 2043," said Matt Pauls, J.D., M.B.A, Chair and Chief Executive Officer, Savara. "With 10 y
Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host one on one meetings and participate in fireside chats at two upcoming healthcare conferences. Fireside Chats: Piper Sandler 37th Annual Healthcare Conference December 2, 2025, 2:30pm ET Evercore ISI 8th Annual Healthcare Conference December 4, 2025, 10:00am ET The live webcasts and subsequent replays will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on r
-- On Track to Resubmit the Biologics License Application (BLA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) in December and Will Request Priority Review -- -- Expect to Submit the MOLBREEVI Marketing Authorization Applications (MAA) for Autoimmune PAP to the European Medicines Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 1Q 2026 -- -- Recently Strengthened Balance Sheet with ~$149.5M Equity Financing, Which Added ~$140M to the ~$124M in Cash, Cash Equivalents, and Short-Term Investments Reported as of September 30, 2025, and Announced $75M Royalty Funding Agreement to Support Potential MOLBREEVI Launch -- Savara
Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in fireside chats at two upcoming healthcare conferences. Fireside Chats: Guggenheim 2nd Annual Healthcare Innovation Conference November 10, 2025, 8:30 a.m. ET Jefferies London Healthcare Conference November 19, 2025, 12:00 p.m. GMT The live webcasts and subsequent replays will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused
Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of common stock, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at $4.20 per share. In addition, in lieu of shares of common stock, Savara sold to certain investors that so chose, pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per pre-funded warrant. The aggregate gross proceeds to Savara from the offering were approximately $149.5 million bef
Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per pre-funded warrant, in each case, before deducting underwriting discounts and commissions, for total gross proceeds of $130.0 million. All of the securities to be sold in the offering are being sold by Savara. Savara also granted the underwriters a 30-day option to purchase up to an additional 4,642,
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wells Fargo initiated coverage of Savara with a rating of Overweight and set a new price target of $7.00
H.C. Wainwright upgraded Savara from Neutral to Buy and set a new price target of $5.00
H.C. Wainwright downgraded Savara from Buy to Neutral and set a new price target of $2.00
Wells Fargo initiated coverage of Savara with a rating of Overweight and set a new price target of $8.00
Evercore ISI downgraded Savara from Outperform to In-line and set a new price target of $5.00 from $7.00 previously
JMP Securities initiated coverage of Savara with a rating of Mkt Outperform and set a new price target of $8.00
Guggenheim initiated coverage of Savara with a rating of Buy and set a new price target of $7.00
Jefferies upgraded Savara from Hold to Buy and set a new price target of $4.00 from $2.00 previously
Jefferies downgraded Savara from Buy to Hold and set a new price target of $2.00
Piper Sandler initiated coverage of Savara with a rating of Overweight and set a new price target of $7.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
Live Leadership Updates
Mr. Parker has More Than 25 Years of Commercial Leadership Experience and has Launched Multiple Rare Disease Products Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Mr. Parker is a seasoned global commercial leader with more than 25 years of experience in the healthcare and biotech industry. Throughout his career, he has developed and executed global commercial plans, including market expansion activities, built high-performance teams, and launched multiple successful rare disease products. Mr. Parker is responsible
Pivotal Phase 3 IMPALA-2 Trial Remains On-Track, Top Line Data Expected End of 2Q 2024 IMPALA-2 is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Received Acceptance from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) on a Revised Pediatric Investigation Plan (PIP) for Molgramostim in aPAP Appoints Raymond Pratt, M.D., Chief Medical Officer Company Ends Quarter with ~$134M, Believes it is Sufficiently Capitalized Through 2025 Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory disease
Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022. "We appreciate Dr. Chowdhury's contributions during his tenure with the company," said Matt Pauls, Chair and CEO, Savara. "His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future." "I am pleased to have been part of the Savara team and wish the company success in the continued development of molgramostim for the treatment of the rare lung
Live finance-specific insights
Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24 (Secondary Endpoint) 97% of Patients Completed Double-Blind Treatment Through Week 48 with No Trial Drug Related Adverse Events Leading to Discontinuation 100% of Patients Completing the 48-Week Double-Blind Period Elected to Participate in the 96-Week Open-Label Period Company Plans to Complete BLA Submission in 1H 2025 Company to Host Webcast Conference Call Today, Ju
Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aPAP. The Company plans to issue a press release sharing the top line results at approximately 6:30am ET tomorrow, prior to the start of the c
This live feed shows all institutional transactions in real time.
SC 13G - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)
SC 13G - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)
SC 13D/A - Savara Inc (0001160308) (Subject)
SC 13D/A - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)